Advertisements
Let's explore the recent HIV medications that the Ministry of Health has included in SUS.
Now, individuals treating HIV can access Darunavir 800 mg, Dolutegravir 5 mg, and Raltengravir 100 mg through SUS. The Ministry of Health announced this inclusion, and the Official Gazette of the Union published this measure.
This represents a significant step in treating the virus. Thus, we are presenting more effective, high-quality alternatives to combat it.
In this context, the Secretariat of Science, Technology, Innovation and Health published details about the use of these new HIV medications in SUS. Below, see a summary of each medication.
How do the 3 new HIV medications in SUS work?
Patients who have failed initial treatment use 800 mg Darunavir. This antiretroviral belongs to the protease inhibitor class.
Read also: Exceptional Benefit Will Reach 20,000 Families; See if You Are Eligible
Next, 100 mg granulated Raltengravir is used to prevent vertical transmission of HIV in children at high risk of exposure, namely those born to mothers with the virus. Therefore, they should receive antiretrovirals to prevent transmission.
Finally, children between 2 months and 6 years old will receive Dolutegravir 5 mg. It serves as a complementary or substitute treatment, coming in dispersible tablets to facilitate administration in children.
Deadline for providing the new HIV medications through SUS
After the publication of the ordinances, the Ministry of Health established a 180-day deadline to make HIV medications available through SUS. This period is essential for carrying out all the necessary procedures, from logistical organization to effective distribution at healthcare facilities across the country.
During these days, the Ministry of Health will collaborate with the entities responsible for managing SUS, such as state and municipal health departments, to ensure the inclusion of these medications on the list of available therapies.
Read also: Learn everything about Values to Receive
